Research programme: immunotherapeutic kinoids and toxoids - Neovacs

Drug Profile

Research programme: immunotherapeutic kinoids and toxoids - Neovacs

Alternative Names: Conjugated vaccines - NeoVacs; Debio 0512; E7 toxoid; E7 Δ21-26 toxoid; huTNFα kinoid; iCore toxoid; IL-10 kinoid; IL-4 kinoid; Interleukin-4 kinoid; Vascular endothelial growth factor kinoid; VEGF-kinoid

Latest Information Update: 06 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neovacs
  • Developer Debiopharm; Neovacs
  • Class Vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants; Interleukin 4 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Hypersensitivity; Solid tumours
  • Discontinued Cachexia; Hepatitis C; Human papillomavirus infections

Most Recent Events

  • 05 Jan 2017 NeoVacs and Sunnybrook Research Institute of Toronto enter into an agreement to collaborate for preclinical development of VEGF Kinoid for Colorectal and Ovarian cancers
  • 20 Jan 2016 NeoVacs and Stellar Biotechnologies enters into a joint venture to manufacture conjugated vaccines including IFN-α kinoid in France
  • 18 Sep 2014 Neovacs states its decision to resume preclinical development of VEGF-kinoid in Age-related macular degeneration and solid tumours and IL-4 kinoid in allergies (hypersensitivity)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top